| Literature DB >> 19556337 |
Yasushi Ichikawa1, Ayumu Goto, Satoru Hirokawa, Miyuki Kijima, Takashi Ishikawa, Takashi Chishima, Hirokazu Suwa, Harumi Yamamoto, Shigeru Yamagishi, Shunichi Osada, Mitsuyoshi Ota, Shoichi Fujii.
Abstract
Allergic reactions to oxaliplatin can be severe and are an important cause of discontinuation of treatment. A retrospective review was performed for 105 patients who received FOLFOX regimens between May 2005 and June 2007. Twenty-five cases (23.8%) of allergic reactions were identified, including 9 late onset reactions (8.6%) and 16 immediate reactions (15.2%). Severe allergy (Grades 3 and 4) occurred in seven patients (6.7%). Re-introduction of FOLFOX was attempted for seven immediate onset patients with a severity grade of 1 or 2, and three of these patients (42.9%) showed relapse of allergy. In approximately 10% of the patients, FOLFOX had to be discontinued due to allergy before the disease became refractory to the regimen. Our experience indicates that allergy to oxaliplatin may be a significant concern and that methods are required for suppression of this allergy.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19556337 DOI: 10.1093/jjco/hyp070
Source DB: PubMed Journal: Jpn J Clin Oncol ISSN: 0368-2811 Impact factor: 3.019